The estimated Net Worth of Clay Thorp is at least $8.02 Million dollars as of 25 September 2023. Mr. Thorp owns over 10,000 units of PhaseBio Pharmaceuticals stock worth over $2,841 and over the last 8 years he sold PHAS stock worth over $7,775,504. In addition, he makes $242,892 as Co-Founder und Independent Chairman of the Board at PhaseBio Pharmaceuticals.
Clay has made over 25 trades of the PhaseBio Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of PHAS stock worth $8,600 on 25 September 2023.
The largest trade he's ever made was buying 785,714 units of PhaseBio Pharmaceuticals stock on 7 June 2016 worth over $5,499,998. On average, Clay trades about 58,447 units every 63 days since 2016. As of 25 September 2023 he still owns at least 40,522 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Mr. Thorp stock trades at the bottom of the page.
Clay B. Thorp serves as Co-Founder, Independent Chairman of the Board of the Company. Mr. Thorp has served as Chair of our Board of Directors since November 2014. In 2001, Mr. Thorp co-founded and has since served as general partner of Hatteras Venture Partners. He has served on the board of directors of Clearside Biomedical, Inc. since January 2012. Mr. Thorp received a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University. Our Board of Directors believes that Mr. Thorp is qualified to serve as a director based on his institutional knowledge of our company and his experience as an entrepreneur and an investor in life sciences companies.
As the Co-Founder und Independent Chairman of the Board of PhaseBio Pharmaceuticals, the total compensation of Clay Thorp at PhaseBio Pharmaceuticals is $242,892. There are 6 executives at PhaseBio Pharmaceuticals getting paid more, with Jonathan Mow having the highest compensation of $1,203,070.
Clay Thorp is 51, he's been the Co-Founder und Independent Chairman of the Board of PhaseBio Pharmaceuticals since 2014. There are 14 older and 4 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
Clay's mailing address filed with the SEC is C/O CLEARSIDE BIOMEDICAL, INC., 900 NORTH POINT PARKWAY, SUITE 200, ALPHARETTA, GA, 30005.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... und Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: